Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Net Margin: 2009-2025

Historic Net Margin for Madrigal Pharmaceuticals (MDGL) over the last 9 years, with Sep 2025 value amounting to -38.68%.

  • Madrigal Pharmaceuticals' Net Margin rose 13336.00% to -38.68% in Q3 2025 from the same period last year, while for Sep 2025 it was -38.62%, marking a year-over-year increase of 71304.00%. This contributed to the annual value of -258.64% for FY2024, which is 319783.00% down from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Net Margin stood at -38.68% for Q3 2025, which was down 94.88% from -19.85% recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Net Margin registered a high of 15,477.02% during Q2 2022, and its lowest value of -124,132.69% during Q4 2021.
  • Its 3-year average for Net Margin is 1,305.20%, with a median of -19.85% in 2025.
  • In the last 5 years, Madrigal Pharmaceuticals' Net Margin tumbled by 11,044,681bps in 2021 and then soared by 13,830,843bps in 2022.
  • Quarterly analysis of 5 years shows Madrigal Pharmaceuticals' Net Margin stood at -124,132.69% in 2021, then surged by 13,830,843bps to 14,175.74% in 2022, then tumbled by 1,135,041bps to 2,825.33% in 2023, then slumped by 288,284bps to -57.51% in 2024, then spiked by 13,336bps to -38.68% in 2025.
  • Its Net Margin stands at -38.68% for Q3 2025, versus -19.85% for Q2 2025 and -53.36% for Q1 2025.